Compugen

$9.63
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.37 (+4.13%) Today
+$0.30 (+3.22%) As of 10:06 AM UTC after-hours

Why Robinhood?

You can buy or sell Compugen and other stocks, options, and ETFs commission-free!

About CGEN

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses its research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel. The listed name for CGEN is Compugen Ltd. Ordinary Shares.

CEO
Anat Cohen-Dayag
Employees
61
Headquarters
Holon, Tel Aviv
Founded
1993
Market Cap
906.79M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.02M
High Today
$9.43
Low Today
$8.50
Open Price
$9.01
Volume
3.24M
52 Week High
$19.90
52 Week Low
$5.94

CGEN News

BenzingaFeb 25

Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies

Compugen Ltd (NASDAQ: CGEN) reports updated data from its Phase 1 dose-escalation and expansion study of COM701 as a monotherapy and a dose-escalation combinati

CGEN Earnings

-$0.14
-$0.12
-$0.10
-$0.08
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.10 per share
Actual
-$0.10 per share
Replay Earnings Call

You May Also Like

VOOG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure